MedTrace Logo

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04543188 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-10-23

Study results available
· View outcomes & findings →

Summary

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.

Conditions

  • Malignant Melanoma
  • Carcinoma, Non-Small-Cell Lung
  • Brain Neoplasms, Primary
  • Brain Neoplasms
  • Malignant Neoplasms

Interventions

DRUG

PF-07284890

PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)

DRUG

Binimetinib

Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

DRUG

Midazolam

Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2024-03-20
Completion
2024-03-20
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04543188 on ClinicalTrials.gov